R&D

Inovio Presents Phase II Clinical Efficacy Data at the 15th World Vaccine Congress

Inovio Presents Phase II Clinical Efficacy Data at the 15th World Vaccine Congress

Written by on September 15, 2014 in Prophylactic Vaccines, R&D, Therapeutic Vaccines, Vaccines Live with 0 Comments

With the 15th World Vaccine Congress on 13 – 15 October in Brussels is just next month I conducted an interview to one of our key speakers, Dr. Niranjan Y. Sardesai (COO, Inovio Pharmaceuticals, Inc.) to give you further insight into his new exciting clinical data and current challenges in developing cancer DNA vaccines.  Dr. […]

Continue Reading

UCC Developing Vaccine Patch To Combat Malaria

UCC Developing Vaccine Patch To Combat Malaria

Written by on September 4, 2014 in Featured on App, News, R&D with 0 Comments

Researchers at University College Cork in Ireland have developed a patch that delivers small doses of a vaccine through microscopic needles A new malaria vaccine administered through a micro-needle patch has been developed by scientists at the school of pharmacy at the University College Cork in Ireland. The patch itself is composed of microscopic silicon […]

Continue Reading

Therapeutic

Japan May Provide West African Countries With Unapproved Ebola Treatment

Japan May Provide West African Countries With Unapproved Ebola Treatment

Written by on August 27, 2014 in Featured on App, News, Therapeutic Vaccines with 0 Comments

The Japanese government is ready to provide Ebola afflicted countries an experimental drug that has not yet been approved by the WHO On Monday the 27th of August, Japan’s Chief Cabinet Secretary Yoshihide Suga announced that the country is willing to donate a flu drug called Favipiravir to aid the Ebola crisis in west Africa. […]

Continue Reading

Merck Tecemotide Cancer Vaccine Fails Phase II Clinical Trial Goal

Merck Tecemotide Cancer Vaccine Fails Phase II Clinical Trial Goal

Written by on August 22, 2014 in Featured on App, News, Therapeutic Vaccines with 0 Comments

Merck’s therapeutic cancer vaccine candidate, tecemotide, has shown no treatment effect in any trial endpoints Merck’s experimental therapeutic cancer vaccine,  in partnership with Oncothyreon,  has recently shown disappointing clinical trial results after the drug failed to meet its primary endpoint, as well as several other secondary endpoints. Many pharmaceutical companies are currently developing therapeutic cancer […]

Continue Reading

Prophylactic

Johnson & Johnson To Fast Track Ebola Vaccine Trials

Johnson & Johnson To Fast Track Ebola Vaccine Trials

Written by on September 5, 2014 in Featured on App, News, Prophylactic Vaccines with 0 Comments

Amongst the flurry of efforts to combat the West African Ebola outbreak, Johnson & Johnson is trying its hand at developing a vaccine Johnson & Johnson can be counted amongst the ranks of yet another pharmaceutical company that has joined the race to develop an Ebola vaccine. Thus far, the most advanced vaccine candidate is Glaxo […]

Continue Reading

New Positive Dengue Vaccine Results From Sanofi’s Biggest Trial Yet

New Positive Dengue Vaccine Results From Sanofi’s Biggest Trial Yet

Written by on September 3, 2014 in Emerging Markets, Featured on App, Prophylactic Vaccines with 0 Comments

Sanofi today announced the positive results of a 20,000 strong phase III trial of their pioneering dengue vaccine This final study from Sanofi Pasteur, Sanofi’s vaccine arm, has demonstrated a 60.8 reduction in cases of dengue  fever amongst it’s 20,875 strong population of 9-16 year olds in Latin America. This was accompanied by a 80% […]

Continue Reading

Flu

Flu Vaccine Nasal Spray For Kids May Be More Cost Effective

Flu Vaccine Nasal Spray For Kids May Be More Cost Effective

Written by on September 2, 2014 in Featured on App, Flu, News with 0 Comments

As Flu season approaches, a study reveals that a nasal spray vaccine may be more cost effective to administer to children A study that has appeared in a recent issue of The American Journal of Pharmacy Benefits has analysed the cost-effectiveness of a nasal spray form of the flu vaccine versus the standard needle shot. […]

Continue Reading

A Universal Flu Vaccine: Could Rare Flu Strains be the Answer?

A Universal Flu Vaccine: Could Rare Flu Strains be the Answer?

Written by on August 27, 2014 in Antibodies, Featured on App, Flu, News with 2 Comments

Research suggests that vaccinations against rare strains of bird flu would be highly effective against a broad range of influenza viruses A study by the Emory Vaccine Centre in Atlanta has found that exposure to rare and uncommon flu strains results in the production of broadly effective antibodies. The study thus begs the question: should […]

Continue Reading

Regulation & Policy

NIH Finds Unauthorised Toxic Samples In Safety Sweep

NIH Finds Unauthorised Toxic Samples In Safety Sweep

Written by on September 10, 2014 in Featured on App, News, Regulation and Policy with 0 Comments

Safety sweep of the NIH reveals presence of five dangerous toxic samples In July 2014, a number of unauthorised smallpox samples were discovered at the NIH’s headquarters in Bethseda, Maryland. This discovery spurred on a safety sweep of the NIH headquarters to verify the presence of any other unauthorised biological samples and toxins. On the […]

Continue Reading

Focus on the Children: New study finds key to improving vaccine coverage

Focus on the Children: New study finds key to improving vaccine coverage

Written by on August 22, 2014 in Regulation and Policy with 0 Comments

A new report shows the power of child orientated pro-vaccine messages when trying to convince parents to vaccinate their children A new study, published earlier this month in Pediatrics, has shown that, when trying to convince parents of young children, that emphasizing the benefits to their infant is more effective than pushing home the societal benefits of […]

Continue Reading

Emerging Markets

The State of the Art of Electronic Health Records – Infographic

The State of the Art of Electronic Health Records – Infographic

Written by on August 22, 2014 in Emerging Markets, News with 0 Comments

In the next 10 years, data science and software will do more for medicine than all of the biological sciences together” Vinod Khosla, venture capitalist Last year, Vaccine Nation reported on research suggesting that the adoption of Electronic Health Records (EHR) could dramatically increase the ability of public health authorities to track immunizations amongst patient. […]

Continue Reading

Ebola Treatment Centre: An Interactive Guide

Ebola Treatment Centre: An Interactive Guide

Written by on August 19, 2014 in Emerging Markets, Featured on App, News with 0 Comments

The Golden Number: 42 Days With a while to wait before we see an approved Ebola vaccine become available, the virus must be effectively contained in order to see an end to the outbreak. The time it takes for symptoms to appear after exposure to the virus is known as the incubation period – and […]

Continue Reading

Supply Chain

The HPV Cancer Vaccine: Two Doses May Be Enough

The HPV Cancer Vaccine: Two Doses May Be Enough

Written by on August 28, 2014 in Featured on App, News, Prophylactic Vaccines, Supply Chain with 0 Comments

Studies have shown that two, instead of three doses, of the HPV vaccine may be enough to prevent the virus On Monday the 25th of August, the 29th International Papillomavirus Conference came to a close in Seattle, USA. Amongst the most hotly debated topics at the conference was lowering the number of doses of the […]

Continue Reading

Lost Small Pox Vials and Anthrax Mishaps

Lost Small Pox Vials and Anthrax Mishaps

Written by on July 15, 2014 in News, Regulation and Policy, Supply Chain with 0 Comments

  Will small pox and anthrax biosafety concerns undermine vital research? Last week the US Centres for Disease Control and Prevention announced that 6 small pox vials had been discovered on the 1st of July during the clearing out of an old laboratory at the Nationality Institute of Health’s (NIH) Bethesda campus, Maryland. The six […]

Continue Reading

Strategy and Partnering

Whistleblowers Reveal Merck Misrepresented Mumps Vaccine Efficacy

Whistleblowers Reveal Merck Misrepresented Mumps Vaccine Efficacy

Written by on September 10, 2014 in Featured on App, News, Partnering and Corporate strategy with 0 Comments

Two former Merck scientists have filed lawsuits against the company for misrepresenting efficacy results of its mumps vaccine Two former virologists for Merck have filed lawsuits against the company for misrepresenting efficacy results of its mumps vaccine. A US district judge from Pennsylvania, Darnell Jones II, has ruled that the pair of whistleblowers have provided […]

Continue Reading

Advaxis and Merck Partnership for Immunotherapy Prostate Cancer Drug Trial

Advaxis and Merck Partnership for Immunotherapy Prostate Cancer Drug Trial

Written by on September 4, 2014 in Featured on App, News, Partnering and Corporate strategy with 0 Comments

Advaxis and Merck have formed a partnership to conduct a clinical trial with their experimental prostate cancer drugs Advaxis and Merck have formed a partnership to test their experimental prostate cancer drugs, ADXS-PSA and anti PD-1 antibody pembrolizumab, to see if the combination of these two drugs will yield psoitive results in a phase I/II trial […]

Continue Reading

Other Recent Posts

Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer

September 12, 2014 Merck announced today that its biopharmaceutical division Merck Serono will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC). Luciano Rossetti, Global Head of Research & Development at Merck Serono, said: “While the […]

Continue Reading

European Committee for Medicinal Products for Human Use approves  update to Gardasil® SmPC to include long-term protection data

Immunogenicity and effectiveness data from long-term follow-up of Gardasil® studies demonstrates sustained protection against HPV 6, 11, 16 and 18 disease September 12, 2014 Sanofi Pasteur MSD announced today that the Summary of Product characteristics (SmPC) of Gardasil has been updated to include new data related to long-term protection. (1) The duration of protection of Gardasil […]

Continue Reading

Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate

September 11, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the initiation of a Phase 2a trial for GEN-004, the Company’s universal vaccine candidate against pneumococcus. The trial is designed to evaluate the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by […]

Continue Reading

Top
Geolocation